Panacea Biotec Ltd Stock Analysis

BSE: 531349 | NSE: PANACEABIO | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 06-Feb-2023 18:01
122.10 0.30 (0.25%)

DeciZen - Make an Informed Decision on Panacea Biotec

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Panacea Biotec Price Chart

P/E Ratio ( SA) :
Market Cap :
747.9 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Panacea Biotec Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Panacea Biotec Ltd is a below average quality company.

2. Is Panacea Biotec Ltd undervalued or overvalued?

The key valuation ratios of Panacea Biotec Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Panacea Biotec Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Panacea Biotec Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Panacea Biotec:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Panacea Biotec Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % -9.1%-6.3%0.4%3.4%2.1%0.3%-10%-1.8%-1.5%-16.5%-
Value Creation Index -1.7-1.5-1.0-0.8-0.9-1.0-1.7-1.1-1.1-2.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 596498679647530574444490344236190
YoY Gr. Rt. %--16.5%36.5%-4.8%-18.1%8.3%-22.7%10.3%-29.8%-31.5%-
Adj EPS -35.5-32.5-9.7-4.6-6.6-11.1-32.1-19.8-2.7-15.2-21
BVPS (₹) 30.829.218.518.574.463.468.3140.58367.854.5
Adj Net Profit -217-199-59.4-28.2-40.6-67.7-196-121-16.6-93.2-129
Cash Flow from Ops. -39.353.244.897.9104172107-82.938.3-52.7-
Debt/CF from Ops. -23.518.622.710.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -9.8%-15%-19.1%-31.5%
BVPS 9.2-1.9-0.3-18.3
Share Price -0.8% -15.3% -1.7% -46%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % -31.6-35.4-10.8-5.2-8.2-16-48.7-18.5-2.4-20.2-34.4
Op. Profit Mgn % -8.2-16.711.218.714.715.2-
Net Profit Mgn % -36.5-40-8.7-4.4-7.7-11.8-44.2-24.8-4.8-39.6-67.8
Debt to Equity
Working Cap Days 392409288311391359666651596642372
Cash Conv. Cycle 13670122647-81-39-20600

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at -20.56%

Latest Financials - Panacea Biotec Ltd.

Standalone Consolidated
TTM EPS (₹) -21 187.4
TTM Sales (₹ Cr.) 190 512
BVPS (₹.) 54.5 131.9
Reserves (₹ Cr.) 328 802
P/BV 2.24 0.91
PE 0.00 0.64
From the Market
52 Week Low / High (₹) 120.00 / 243.65
All Time Low / High (₹) 3.35 / 531.00
Market Cap (₹ Cr.) 748
Equity (₹ Cr.) 6.1
Face Value (₹) 1
Industry PE 36.3

Management X-Ray of Panacea Biotec :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *69.3669.3694.2794.2794.2794.
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Panacea Biotec

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Panacea Biotec Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Panacea Biotec on 06-Feb-2023 18:01 is : 122.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-Feb-2023 18:01 the market cap of Panacea Biotec stood at ₹ 747.9.
The latest PE ratio of Panacea Biotec as of 06-Feb-2023 18:01 is 0.00.
The latest PB ratio of Panacea Biotec as of 06-Feb-2023 18:01 is 2.24
The 52-week high of Panacea Biotec is ₹ 243.7 and the 52-week low is ₹ 120.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Panacea Biotec is ₹ 190.1 ( Cr.) .

About Panacea Biotec Ltd

The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2006), as well as among the top 50 pharmaceutical companies (as per ORG IMS July 2006) of India.

The company has been granted patents across countries like USA, U.K., France, Germany, Italy, Sweden, Denmark, Spain, Finland, Switzerland, The Netherlands, New Zealand, Mexico, Brazil, Nigeria, Zimbabwe, Australia, South Africa, Japan, Russia, Canada, Ukraine, Korea and China are among others.

Collaboration/ Strategic alliances The company has collaborated with Cambridge Biostability, U.K to develop thermo stable vaccines.

It has collaborated with National Institute of Immunology, India for Japanese Encephalitis candidate vaccine.

PBL has entered in strategic alliance with Biotech Consortium India to develop, manufacture and market of Anthrax vaccine.

The company has entered into an in-licensing arrangement with National Institute of Health, USA for use of a peptide based product for generation of hair follicles and hair growth.

The company has collaborated with Netherlands Vaccine Institute for inactivated polio vaccine.

It has collaborated with NRDC- India for Foot & Mouth Disease vaccine for veterinary use and Bio Farma-Indonesia for Measles vaccine.

The exclusive products based on patented Drug Delivery System include Panimun Bioral (Cyclosporine), Willgo, ThankGod (for comprehensive management of haemorrohoids), Xeed (anti-tubercular FDC with innovative Drug Delivery for optimum bioavailability of Rifampicin), Nimulid Safeinject, Nimulid MD, Nimulid Transgel. 

Commencing fiscal 2008, the company plans for international marketing of novel NDDS based pharmaceutical formulation products to the international markets, like USA, U.K., Germany, France, Latin American countries and Italy through marketing collaborations and are on the look out for partners for distribution & marketing.

Business areas Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). The company has a team of 200 scientists working on different aspect of research across its four R&D centers.

Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. It is obtaining pre-qualifications for others vaccines. The company markets its vaccines through Chiron Panacea Vaccines, this is a 50:50 joint venture with Novartis Vaccines, U.K

Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant.

Panacea Biotec in 2009 signed an agreement with Popular Pharma for technology transfer, marketing and distribution of vaccines. Popular Pharma is engaged in manufacturing life saving drugs and has presence in various countries.

In 2010 Panacea Biotech's Baddi unit gets US FDA approval
In 2011 PanaceBiotec - Panacea Biotec Launches - PacliALL
In 2012 Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria
PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit
PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical
Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now